BIVALIRUDIN 250 MG
BIVALIRUDIN : 250 MG · DIN 02450402 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED PRE MARKET
What is BIVALIRUDIN?
BIVALIRUDIN 250 MG contains BIVALIRUDIN : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02450402, held by SANDOZ CANADA INCORPORATED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 01-Aug-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BIVALIRUDIN used for?
Bivalirudin is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention and in the treatment of patients with moderate to high risk acute coronary syndromes due to unstable angina or non-ST-segment elevation in whom early percutaneous coronary intervention is planned. Bivalirudin is also indicated for the treatment of patients with acute coronary syndromes due to ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Bivalirudin is also indicated in patients with or at risk of heparin induced thrombocytopenia or heparin induced thrombocytopenia thrombosis syndrome (HIT/TS) undergoing PCI or cardiac surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02450402 |
|---|---|
| Brand name | BIVALIRUDIN |
| Generic / active ingredient | BIVALIRUDIN : 250 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 250 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AE06 BIVALIRUDIN |
| AHFS class | 20:12.04.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 01-Aug-2018 |
How is it stored and handled?
null
How is it supplied?
null
Is BIVALIRUDIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by AVIR PHARMA INC., last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B01AE06 BIVALIRUDIN. 5 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ANGIOMAX | 250 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02246533 |
| BIVALIRUDIN FOR INJECTION | 250 MG | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02435268 |
| BIVALIRUDIN FOR INJECTION | 250 MG | POWDER FOR SOLUTION | JUNO PHARMACEUTICALS CORP. | MARKETED | DIN 02511452 |
| BIVALIRUDIN FOR INJECTION | 250 MG | POWDER FOR SOLUTION | FORMATIVE PHARMA INC. | MARKETED | DIN 02539586 |
| BIVALIRUDIN INJECTION | 5 MG | SOLUTION | AVIR PHARMA INC. | MARKETED | DIN 02505517 |
| BIVALIRUDIN FOR INJECTION | 250 MG | POWDER FOR SOLUTION | DR REDDY'S LABORATORIES LTD | CANCELLED PRE MARKET | DIN 02518643 |
Who else supplies BIVALIRUDIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BIVALIRUDIN appears in 8 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.